|
C9ORF5 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.66720000005505E-06 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00879999999737E-05 |
| Normal-vs-Stage2 |
2.362900E-04 |
| Normal-vs-Stage3 |
2.79700000049843E-07 |
| Normal-vs-Stage4 |
2.15130000003061E-06 |
| Stage1-vs-Stage2 |
8.522600E-01 |
| Stage1-vs-Stage3 |
6.737600E-02 |
| Stage1-vs-Stage4 |
1.474410E-01 |
| Stage2-vs-Stage3 |
2.718800E-01 |
| Stage2-vs-Stage4 |
3.184000E-01 |
| Stage3-vs-Stage4 |
9.374000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
5.9537999996806E-07 |
| Normal-vs-AfricanAmerican |
5.826100E-02 |
| Normal-vs-Asian |
2.49179999999294E-05 |
| Caucasian-vs-AfricanAmerican |
6.761500E-02 |
| Caucasian-vs-Asian |
8.484200E-01 |
| AfricanAmerican-vs-Asian |
1.493430E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
9.41869999993017E-07 |
| Normal-vs-Female |
2.90560000504314E-08 |
| Male-vs-Female |
3.634400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.41129999997602E-06 |
| Normal-vs-Age(41-60Yrs) |
1.58840000041849E-07 |
| Normal-vs-Age(61-80Yrs) |
8.03589999986976E-07 |
| Normal-vs-Age(81-100Yrs) |
2.315800E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.963600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.857990E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.265780E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.781200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.727800E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.503000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.425600E-04 |
| Classical-VS-Follicular |
9.658400E-01 |
| Classical-VS-Other |
6.833400E-01 |
| Classical-VS-Normal |
2.49849999999219E-05 |
| Tall-VS-Follicular |
1.643320E-03 |
| Tall-VS-Other |
2.179200E-01 |
| Tall-VS-Normal |
4.75609995831405E-09 |
| Follicular-VS-Other |
6.819800E-01 |
| Follicular-VS-Normal |
1.239790E-04 |
| Other-VS-Normal |
4.239700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.21369999997556E-06 |
| Normal-vs-N1 |
8.1341000002233E-07 |
| N0-vs-N1 |
1.918820E-01 |
|
|
